Moseley Investment Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-5,524
Closed -$338K 168
2021
Q4
$338K Sell
5,524
-65
-1% -$4.49K 0.15% 138
2021
Q3
$418K Sell
5,589
-448
-7% -$37.6K 0.21% 112
2021
Q2
$558K Buy
6,037
+322
+6% +$27.4K 0.27% 89
2021
Q1
$507K Buy
+5,715
New +$567K 0.28% 92

Other funds holding ARKG

Moseley Investment Management's ARKG Position: Q1 2022 in Review

Moseley Investment Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 5,524 shares — an estimated $338K sold.

Moseley Investment Management first reported a position in ARKG in Q1 2021 and held it in 4 quarters. The position peaked at $558K in Q2 2021. 388 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

  • Moseley Investment Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
  • Moseley Investment Management sold 5,524 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $338K.
  • Moseley Investment Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 4 quarters.
  • Moseley Investment Management's ARK Genomic Revolution ETF position peaked at $558K in Q2 2021.
  • 388 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Moseley Investment Management's 13F filing for Q1 2022, filed 21 Apr 2022.